DOTS and drug resistance: a silver lining to a darkening cloud.
Chaisson
R E
RE
Coberly
J S
JS
De Cock
K M
KM
D000995:Antitubercular Agents / Q000008:administration & dosage*; D001902:Botswana / Q000453:epidemiology; D015897:Comorbidity; D004352:Drug Resistance, Microbial; D014943:Global Health; D015658:HIV Infections / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D010349:Patient Compliance; D015995:Prevalence; D016730:Program Development; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy / Q000453:epidemiology* / Q000517:prevention & control; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy / Q000453:epidemiology* / Q000517:prevention & control
D000995:Antitubercular Agents